Anti-Transthyretin Antibodies for Non-Native TTR Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for transthyretin (TTR)-related amyloid diseases are inadequate, leading to misdiagnosis and delayed treatment due to the inability to effectively detect non-native TTR forms, which are associated with diseases like familial amyloid polyneuropathy and cardiomyopathy.
Innovation Solution
Development of anti-transthyretin antibodies that selectively bind to non-native TTR forms, including mutant and oligomeric TTR, under physiologically relevant conditions, allowing for early detection and differentiation from native TTR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then general TTR detection is possible, but accurate differentiation between native and non-native TTR forms cannot be achieved
Solution Approach 1:
The patent develops antibodies with specialized local binding properties that recognize specific conformational features of non-native TTR forms. The antibodies are designed to bind to epitopes exposed only in misfolded or aggregated states, providing localized detection capability that distinguishes pathological forms from native TTR without requiring general detection methods.
Solution Approach 2:
The invention exploits conformational parameter changes in TTR that occur during amyloidogenesis. By detecting structural transitions from native tetrameric form to non-native monomeric, oligomeric, or fibrillar forms, the antibodies enable differentiation based on structural parameters rather than simply presence/absence detection, thereby improving diagnostic accuracy.
2Loss of time
If early detection methods are developed, then misdiagnosis can be reduced, but detection of non-native TTR forms under physiologically relevant conditions is currently impossible
Solution Approach 1:
The patent employs antibodies that are pre-configured to recognize non-native TTR conformations under physiological conditions. These antibodies are designed in advance to bind to specific epitopes that become exposed during early stages of TTR misfolding, enabling detection before significant aggregation occurs. This preliminary detection capability allows for early diagnosis without requiring complex sample preparation or non-physiological detection conditions.
3Measurement precision
If selective binding to non-native TTR is achieved, then early diagnosis is enabled, but differentiation from native TTR forms becomes challenging
Solution Approach 1:
The patent uses antibodies as intermediary molecules that bridge the gap between non-native TTR forms and detection systems. These antibodies serve as specific mediators that bind preferentially to conformational epitopes on misfolded TTR while showing minimal cross-reactivity with native forms. This intermediary approach enables selective detection through relatively simple assay formats, avoiding the need for complex differentiation procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies enable accurate detection of non-native TTR, facilitating early diagnosis and treatment of TTR-related amyloid diseases by distinguishing between native and non-native TTR forms, potentially reducing misdiagnosis and improving patient outcomes.
Implementation Method 1
anti-transthyretin antibodies that selectively bind to non-native TTR forms, including mutant and oligomeric TTR, under physiologically relevant conditions, allowing for early detection and differentiation from native TTR
Data Source
AI summary
The present invention provides compositions comprising anti-transthyretin antibodies. The compositions are particularly useful for diagnosis, prognosis and/or treatment of amyloid diseases or symptoms thereof.